Brainsway sees good interim results in Parkinson's trial

There were improvements in specific motor functions.

Transcranial magnetic stimulation biotech company Brainsway Ltd. (TASE:BRIN) reported interim results from its clinical trial at Sheba Medical Center Tel Hashomer Hospital, which is studying its technology as a treatment for Parkinson's disease.

Preliminary results show that the treatment has not shown side effects, except for slight and passing headaches among some patients. At the same time, there were improvements in specific motor functions. The results are statistically significant, though the relatively small number of patients (about 27) and the differences among them makes it difficult to estimate the clinical significance.

Sheba intends to continue the trial.

Shares in Brainsway initially rose about 9% on the news, though the gains moderated and it was up 2.3% by late morning. Brainsway shares have more than doubled in 2009.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018